Mattke Soeren, Liu Hangsheng, Orr Patrick
Rand Health Q. 2016 Jun 20;6(1):9.
In this article, the authors explore why medical device innovation has traditionally been geared so thoroughly toward improving performance, with little regard to cost. They argue that the changing incentives in the health care sector and the move to value-based payment models, accelerated by the implementation of the Affordable Care Act, will force device manufacturers to redirect investments from the spectacular toward the prudent, which they dub "the end of sexy." The authors explore consequences for manufacturers, investors, and policymakers.
在本文中，作者探讨了为何医疗设备创新传统上一直如此彻底地致力于提高性能，而很少考虑成本。他们认为，医疗保健领域不断变化的激励措施以及向基于价值的支付模式的转变（因《平价医疗法案》的实施而加速）将迫使设备制造商将投资从追求引人注目的产品转向更为审慎的产品，他们将此称为“性感时代的终结”。作者探讨了这一转变对制造商、投资者和政策制定者的影响。
